Vincerx Pharma, Inc. announced that In connection with the strategic plan, Hermes Garban, M.D., Ph.D., will depart from his role as the company's Chief Medical Officer on or before August 6, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6794 USD | -1.38% |
|
-4.58% | -42.42% |
14/05 | Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
26/04 | Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.42% | 2.01Cr | |
+18.15% | 12TCr | |
+18.02% | 11TCr | |
+5.07% | 2.29TCr | |
-12.75% | 2.22TCr | |
-9.86% | 1.7TCr | |
-14.97% | 1.69TCr | |
-39.94% | 1.69TCr | |
+2.80% | 1.36TCr | |
+27.39% | 1.16TCr |
- Stock Market
- Equities
- VINC Stock
- News Vincerx Pharma, Inc.
- Vincerx Pharma, Inc. Announces Departure of Hermes Garban as Chief Medical Officer, Effective on or Before August 6, 2022